Ви можете залишити Вашу заявку на продукцію, заповнивши заявку в telegram або viber
The combination of a selectively micro-structured abluminal surface (SMS) and Biolimus A9 ™ make BioFreedom ™ Ultra a unique stent. Both iterations of the BioFreedom ™ stent use Biosensors International patented SMS process to allow a uniform dose of BA9 ™ to be coated on to the abluminal surface of the stent, standardizing the drug dose between the two devices. BioFreedom ™ is the predicate device of BioFreedom ™ Ultra allowing to leverage the legacy of the LEADERS FREE clinical trial program.
At least 40% 1 of PCI patients are High Bleeding Risk (HBR) requiring an individualized approach, BioFreedom ™ Ultra provides a more appropriate treatment strategy.
The rapid 28 day transfer of BA9 ™ to the coronary artery and rapid reendothelialization of the stented vessel, make BioFreedom ™ Ultra the most relevant choice of stent for High Bleeding Risk (HBR) patients who cannot tolerate long dual antiplatelet therapy (DAPT).
The LEADERS FREE trial proved superior safety and efficacy of the BioFreedom ™ DCS vs a BMS in the previously understudied and underserved HBR patient population2.